Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
For the latest QIDP listing, please click HERE As of Oct. 9, 2014, there were by my accounting 30 compounds with QIDP designation. Here is the break-down: 31 compounds with QIDP designation 29 antibacterials, 2 antifungals 22 systemically active, 9 for topical administration 13 in Phase 3, 9 in Phase Continue reading QIDP Drugs: Here They Are, All of Them
Since the publication of a series of posters at ICAAC 2014, we finally know what’s hidden behind the ‘Carbavance’ name. ‘Carbavance’ stands for the combination of meropenem with the B-lactamase inhibitor RPX7009 which The Medicines Company (TMC) inlicensed from Rempex Pharmaceuticals a few years ago. This is the ‘Carbavance’ which Continue reading What’s in a Name? Would ‘Carbavance’ Still Smell as Sweet?
Inhibitor of the NDM Enzyme Aspergillomarasmine (AMA) was identified as an inhibitor of the New Delhi metallo-betalactamase (NDM) enzyme. This substance, when combined with meropenem, restored antibiotic activity against an NDM lab strain. AMA is a substance which was already tested in the past in humans. Concerns about interference with human metalloenzymes proved Continue reading Perusing the Literature